Anders Lundstrom appointed CEO of Shield Therapeutics
LONDON: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency, announces that Anders Lundstrom has been appointed as Chief Executive...
Shield Therapeutics commences trading at OTCQX Best Market
LONDON: Shield Therapeutics plc (LON: STX) announced that trading in the Company’s Ordinary Shares of nominal value of £0.015 each began on the OTCQX Best...